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Comparative genetic architectures of schizophrenia in East Asian and European 
populations 
Abstract 
Schizophrenia is a debilitating psychiatric disorder with approximately 1% lifetime risk globally. Large-
scale schizophrenia genetic studies have reported primarily on European ancestry samples, potentially 
missing important biological insights. Here, we report the largest study to date of East Asian participants 
(22,778 schizophrenia cases and 35,362 controls), identifying 21 genome-wide-significant associations in 
19 genetic loci. Common genetic variants that confer risk for schizophrenia have highly similar effects 
between East Asian and European ancestries (genetic correlation = 0.98 ± 0.03), indicating that the 
genetic basis of schizophrenia and its biology are broadly shared across populations. A fixed-effect meta-
analysis including individuals from East Asian and European ancestries identified 208 significant 
associations in 176 genetic loci (53 novel). Trans-ancestry fine-mapping reduced the sets of candidate 
causal variants in 44 loci. Polygenic risk scores had reduced performance when transferred across 
ancestries, highlighting the importance of including sufficient samples of major ancestral groups to 
ensure their generalizability across populations. 
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Author summary 86 
 87 
Schizophrenia is a severe psychiatric disorder with a lifetime risk of about 1% world-wide. Most 88 
large schizophrenia genetic studies have studied people of primarily European ancestry, 89 
potentially missing important biological insights. Here we present a study of East Asian 90 
participants (22,778 schizophrenia cases and 35,362 controls), identifying 21 genome-wide 91 
significant schizophrenia associations in 19 genetic loci. Over the genome, the common genetic 92 
variants that confer risk for schizophrenia have highly similar effects in those of East Asian and 93 
European ancestry (rg=0.98), indicating for the first time that the genetic basis of schizophrenia 94 
and its biology are broadly shared across these world populations. A fixed-effect meta-analysis 95 
including individuals from East Asian and European ancestries revealed 208 genome-wide 96 
significant schizophrenia associations in 176 genetic loci (53 novel). Trans-ancestry fine-97 
mapping more precisely isolated schizophrenia causal alleles in 70% of these loci. Despite 98 
consistent genetic effects across populations, polygenic risk models trained in one population 99 
have reduced performance in the other, highlighting the importance of including all major 100 
ancestral groups with sufficient sample size to ensure the findings have maximum relevance for 101 
all populations.  102 
4 
Schizophrenia is an often disabling psychiatric disorder which occurs worldwide with a lifetime 103 
risk of about 1%1. It is well-established that genetic factors contribute to susceptibility of 104 
schizophrenia. Recently, 145 genetic loci have been associated with schizophrenia in samples 105 
of primarily European ancestry2,3 (EUR) but this still represents the tip of the iceberg with 106 
respect to common variant liability to the disorder: the highly polygenic nature of common 107 
variation underlying this disorder predicts that there are hundreds more loci to be discovered4.  108 
Most genetic studies of schizophrenia have been in EUR samples with relatively few 109 
studies in other populations5–8. This is a significant deficiency for multiple reasons, particularly 110 
as it greatly limits the discovery of biological clues about schizophrenia. For some causal 111 
variants, ancestry-related heterogeneity yields varying allele frequency and linkage 112 
disequilibrium (LD) patterns such that associations that can be detected in one population may 113 
not be readily detected in others. Examples include a nonsense variant in TBC1D4 which 114 
confers muscle insulin resistance and increases risk for type 2 diabetes that is common in 115 
Greenland but is rare or absent in other populations9, several Asian-specific coding variants 116 
which influence blood lipids10, a variant highly protective against alcoholism that is common in 117 
Asian populations but very uncommon elsewhere11, and two loci associated with major 118 
depression12that are more common in the Chinese populations than EUR12,13 (rs12415800: 45% 119 
versus 2%, and rs35936514: 28% versus 6%).  120 
Even if alleles have similar frequencies across populations, the effects of alleles on risk 121 
might be specific to certain populations if there are prominent but local contributions of clinical 122 
heterogeneity, gene-environment (GxE) or gene-gene (GxG) interactions. In addition, there 123 
have been debates about differences in prevalence, symptomatology, etiology, outcome, and 124 
course of illness across geographical regions14–19. Understanding the genetic architecture of 125 
schizophrenia across populations provides insights in whether any differences represent 126 
etiologic heterogeneity on the illness. 127 
Finally, polygenic risk score (PRS) prediction is emerging as a useful tool for studying 128 
the effects of genetic liability, identifying more homogeneous phenotypes, and stratifying 129 
patients, but the applicability of training data from EUR studies to those of non-European 130 
ancestry has not been fully assessed, leaving us with an uncertainty as to the biological 131 
implications and utility in non-Europeans20. 132 
 133 
Schizophrenia genetic associations in the East Asian populations 134 
To systematically examine the genetic architecture of schizophrenia in individuals of East Asian 135 
ancestry (EAS), we compiled 22,778 schizophrenia cases and 35,362 controls from 20 samples 136 
5 
from Singapore, Japan, Indonesia, Korea, Hong Kong, Taiwan, and mainland China (Extended 137 
Data Table 1). Individual-level genotypes were available from 16 samples (Extended Data Table 138 
1a), on which we performed quality control, imputation and association tests (Methods and 139 
Supplementary Table 1). Two samples (TAI-1 and TAI-2) were trio-based and pseudo-controls 140 
were used. Four samples made available summary statistics for 22K-31K selected variants 141 
(Methods) which had been analyzed in published studies7,8.  142 
We used a two-stage study design (Extended Data Table 1a). Stage 1 included 13 143 
samples for which we had individual genotype data (13,305 cases and 16,244 controls after 144 
quality control). Stage 2 incorporated the remaining 7 samples: full genotype data from 3 145 
samples that arrived after the Stage 1 data freeze and summary statistics (for selected variants) 146 
from 4 samples (Extended Data Table 1). Meta-analyses across Stage 1 samples and across all 147 
EAS samples were conducted using a fixed-effect model with inverse-variance weighting. QQ 148 
plots (Extended Data Fig. 1) showed no inflation of test statistics (particularly that ancestry 149 
effects have been well controlled) with λgc=1.14, λ1000=1.01 and LD Score regression
21 (LDSC) 150 
intercept=1.0145±0.011 using Stage 1 samples.  151 
Combining Stages 1 and 2, we found 21 genome-wide significant associations at 19 loci 152 
(Table 1, Fig. 1a and Supplementary Table 2), an additional 14 associations over the most 153 
recent schizophrenia genetic study of Chinese ancestry8. Most associations were characterized 154 
by marked differences in allele frequencies between the EAS and EUR samples: for 15 of 21 155 
loci, the index variants had a higher minor allele frequencies (MAF) in EAS than EUR. The 156 
higher allele frequency potentially confers better power to detect associations in EAS. For 157 
example, we identified a locus (Fig. 1b) with the top association (rs374528934) having strong 158 
evidence in EAS (P = 5 x 10-11) but not in EUR using the Stage 1 samples. rs374528934 has 159 
MAF of 45% in EAS but only 0.7% in EUR. No other variant in this locus is significantly 160 
associated with schizophrenia in EUR. This locus contains CACNA2D2 (the calcium channel 161 
α2δ-2 subunit) associated with childhood epilepsy22,23, and to which the anticonvulsant 162 
medication gabapentin binds, suggesting a path for further therapeutic investigation23. This 163 
finding also adds new evidence to the calcium signaling pathway suggested to be implicated in 164 
psychiatric disorders24,25. The absence of the MHC association is evaluated in Discussion.  165 
 166 
Genetic effects are consistent across populations 167 
While it is assumed that biological pathways underlying complex human disorders are generally 168 
consistent across populations, genetic heterogeneity has been observed. For example, 169 
rs4246905, a variant in the TNFSF15-TNFSF8 locus, has a much larger protective effect for 170 
6 
Crohn’s disease in EAS than EUR (95% confidence interval of odds ratio: 0.52-0.64 vs 0.85-171 
0.89)26. For causal variants, heterogeneity of genetic effect across populations could arise from 172 
clinical heterogeneity, differences in pathophysiology, exposures to different environmental 173 
factors (GxE interaction), or interaction with other genetic factors (GxG interaction) that act non-174 
additively with risk alleles. This large EAS sample allowed us, for the first time, to explore the 175 
heterogeneity of genetic effects influencing liability to schizophrenia across two major world 176 
populations. 177 
Using LDSC21, we found the SNP-heritability of schizophrenia is very similar in EAS 178 
(0.23±0.03) and EUR (0.24±0.02) (Methods and Extended Data Fig. 2a). We also found that the 179 
common-variant genetic correlation for schizophrenia between EAS and EUR was 180 
indistinguishable from 1 (rg=0.98±0.03) (using POPCORN
27, a method designed for cross-181 
ancestry comparisons). This finding indicates that the common variant genetic architecture of 182 
schizophrenia is basically identical across EAS and EUR.  183 
Genetic correlations between schizophrenia and 11 other psychiatric disorders and 184 
behavior traits also showed no significant differences when estimated within EUR and across 185 
EAS-EUR (Extended Data Fig.2b). In agreement with recent reports28–31, we observed 186 
significant positive genetic correlations for schizophrenia with bipolar disorder, major depressive 187 
disorder, anorexia nervosa, neuroticism, autism spectrum disorder, and educational attainment. 188 
We observed significant negative correlations with general intelligence, fluid intelligence score, 189 
prospective memory, and subjective well-being. 190 
We used partitioned LDSC21 to look for heritability enrichment in diverse functional 191 
genomic annotations defined and used in previous publications32,33 (Methods and Extended 192 
Data Figure 2c,d). Using EAS Stage 1 samples, we observed significant enrichment (after 193 
Bonferroni correction) in regions conserved across 29 mammals (Conserved LindbladToh34). No 194 
other annotations were significantly enriched, and there were no significant differences between 195 
EUR-only and EAS-only enrichments (P=0.16, two-sided paired t test).  196 
We identified gene-sets that are enriched for schizophrenia genetic associations using 197 
MAGMA35 and gene-set definitions from a recent schizophrenia exome sequencing study36 198 
(Methods). Despite large differences in sample size and genetic background, the gene-sets 199 
implicated in EAS and EUR samples were highly consistent: we observed no significant 200 
differences between gene-set ranks using the EAS samples from the ranks using EUR samples 201 
(P = 0.72, Wilcoxon test). In addition, 9 of the top 10 gene-sets identified using the EAS 202 
samples are also among the top 10 gene-sets identified using EUR samples (Extended Data 203 
Figure 3).  204 
7 
A study of EUR individuals suggested that common schizophrenia alleles are under 205 
strong background selection3. We performed two analyses and found that the natural selection 206 
signatures, including positive and background selections, are consistent in schizophrenia-207 
associated loci across EAS and EUR populations. First, we compared the signatures in the top 208 
100 associated loci in EAS to those in EUR. Among the selection signatures we calculated 209 
(Methods), none showed a significant difference across populations (Extended Data Figure 4a, 210 
P > 0.05 for all panels, two-sided t test). We next asked whether the population differentiation 211 
drives schizophrenia variants to have different effect in different populations. Using 295 212 
autosomal variants that are genome-wide significant in EAS, EUR or EAS-EUR combined 213 
samples, we did not observe a correlation (R2=0.003, Extended Data Figure 4b) between the 214 
population differentiation (measured by Fst) and the heterogeneity of effect size (measured by 215 
log10P-value from the heterogeneity test across EAS and EUR).  216 
We compared the effect size estimates for schizophrenia associations in EAS versus 217 
those in EUR. A precise comparison requires disease-causal variants and equivalent case and 218 
control ascertainment schemes to avoid heterogeneity driven by differences in LD and 219 
heterogeneity due to differences in cases and in controls. As we do not know the causal alleles 220 
at the associated loci, we used the most significantly associated variants in EAS that are in LD 221 
(R2>0.8) with the most significantly associated variants in EUR at each locus as an 222 
approximation. We also restricted the comparison to variants that have P<10-10 in EUR and 223 
MAF > 10% in EAS as the estimates of the effect sizes for relatively common alleles that 224 
substantially surpass genome-wide significance are least subject to inflationary bias in the 225 
discovery set. None of the 21 associations that met these criteria showed significant differences 226 
in the direction of effect (Fig. 2a) and moreover, the magnitude of the effect size was consistent 227 
across the two populations with a modest bias from the winner’s curse in the discovery (EUR) 228 
samples (slope=0.67±0.09).  229 
 230 
Schizophrenia genetic associations from the meta-analysis of EAS and EUR  231 
As the genetic effects observed in EAS are largely consistent with those observed in EUR, we 232 
performed a meta-analysis including the EUR and EAS samples (Stages 1 and 2) using a fixed-233 
effect model with inverse-variance weighting37. The EUR samples in this analysis (56,418 cases 234 
and 78,818 controls) included all samples of EUR ancestry from the previous publication2 with 235 
the exclusion of three samples of EAS ancestry and the deCODE samples (1,513 cases and 236 
66,236 controls) which only had summary statistics for selected variants. The three EAS 237 
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samples (IMH-1, HNK-1 and JPN-1) excluded from EUR samples were included in our EAS 238 
Stage 1.  239 
We identified 208 independent (both in EAS and EUR) variants associated with 240 
schizophrenia across 176 genetic loci (Fig. 2b and Supplementary Tables 3 and 4), among 241 
which 53 loci were novel (not reported in ref 2,3,7,8). Of the 108 schizophrenia-associated loci 242 
reported in the previous EUR study2, 89 remained significant in this study (Supplementary Table 243 
5). As suggested by Pardiñas et al.3, this reflects an expected over-estimation of the effect sizes 244 
due to the winner’s curse in the previous study, but does not mean the 19 loci not significant in 245 
this study were false-positives in the previous study. In addition, deCODE samples were not 246 
included in this analysis.   247 
 248 
Population diversity improves fine-mapping  249 
Due to LD, disease-associated loci from genome-wide association studies usually implicate 250 
genomic regions containing many associated variants. A number of approaches allow for the 251 
associated variants to be refined to a smaller set of the most plausible (or credible) candidate 252 
causal variants38–41. Loci implicated in psychiatric disorders usually have small effect sizes and 253 
as a result, have generally poor performance using such approaches2,3.  254 
Diversity in genetic background across populations can be used to improve fine-mapping 255 
resolution42. Here we demonstrate that resolution can be improved by exploiting differences in 256 
the patterns of LD between causal (directly associated) and LD (indirectly) associated variants. 257 
Based on the premise that genetic effects are highly consistent across populations, the causal 258 
variants will have consistent effects across populations whereas non-causal variants can have 259 
inconsistent effects due to population-specific LD patterns. We therefore expect causal variants 260 
to have greater statistical significance and less heterogeneity in trans-ancestry meta-analysis 261 
compared to other alleles that are indirectly associated via LD (Extended Data Figure 5). Using 262 
a new algorithm based on this presumption (Methods), we fine-mapped 133 schizophrenia 263 
associations that reached genome-wide significance in the EUR and EAS (Stage 1) combined 264 
meta-analysis (Supplementary Table 6). Stage 2 EAS samples were excluded because not all 265 
had full genome coverage, which confounds the fine-mapping outcome (Methods).  266 
Results from this EAS-EUR trans-ancestry approach improved upon those using only 267 
EUR, with 93 loci mapped to a smaller number of candidate causal variants. For example, a 268 
locus on chromosome 1 (238.8-239.4 Mb) which initially contained 7 potentially causal variants 269 
based on a published fine-mapping method38 and EUR samples was resolved to a single 270 
variant, rs11587347, with 97.6% probability (Fig. 3a). This variant showed strong association in 271 
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both populations, while the other 6 variants are equally associated in EUR but not in EAS (Fig. 272 
3b, c). Over all associations, the median size of the 95% credible set, defined as the minimum 273 
list of variants that were >95% likely to contain the causal variant, dropped from 57 to 34; and 274 
the number of associations mapped to ≤5 variants increased from 8 to 15 (Fig. 3d). The number 275 
of associations mapped to a single variant with greater than 50% probability increased from 16 276 
to 20, and median size of the genomic regions the associations mapped decreased from 277 Kb 277 
to 111 Kb.  278 
Two schizophrenia associations were fine-mapped to coding variants including 279 
SLC39A8 (A391T) with 44.8% probability, and WSCD2 (T226I) with 14.8% probability. The 280 
SLC39A8 A391T variant causes deficiency in manganese homeostasis43 and glycosylation44, 281 
and is associated with Crohn’s disease45, human gut microbiome composition45, hypertension46 282 
and intelligence47. In addition, using a similar strategy as in Huang et al.38, we found a 283 
schizophrenia association (mapped to rs1700006 with 16.1% causal probability) implicating a 284 
conserved transcription factor binding site (MEF2), which is 14 kb downstream of the nicotinic 285 
receptor subunits CHRNA3 and CHRNB4. Finally, we searched for but did not find any 286 
associations that implicate constrained nucleotides near exon splicing junctions48. 287 
  288 
Transferability of genetics across populations   289 
We compared the variance explained across EAS and EUR for genome-wide significant loci, 290 
approximated as  (ref 49), which explain >0.05% of the variance in 291 
either ancestry (Extended Data Fig. 6). While these variants most often have the same effect 292 
across populations, their allele frequencies can differ. Variance explained, combining the effect 293 
size (OR) and prevalence of the risk allele ( ), can be regarded as an approximate measure of 294 
the importance of a causal variant in a population. We found that most of the difference in 295 
variance explained is driven by allele frequency differences. One of the implications of this 296 
observation, as suggested in recent studies20,50,51, is that even if the risk alleles and effect sizes 297 
are primarily shared across populations, the disease predictive power of individual alleles, and 298 
of composite measures of those risk alleles such as PRS, may not be equivalent across 299 
populations.  300 
Here we evaluate this empirically. We assessed how much variation in schizophrenia 301 
risk can be explained in EAS using both EAS Stage 1 and EUR training data. Using a standard 302 
clumping approach, we first computed PRS using a leave-one-out meta-analysis approach with 303 
EAS summary statistics (Methods), which explained ~3% of schizophrenia risk using genome-304 
wide variants on the liability scale (R2 = 0.029 at P=0.5). In contrast, when EUR summary 305 
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statistics were used to calculate PRS in the EAS samples, a maximum of only ~2% of 306 
schizophrenia risk was explained (R2 = 0.022 at P=0.1) despite a greater than 3-fold larger EUR 307 
effective sample size (Fig. 4 and Extended Data Fig. 7). The variance explained across various 308 
P-value thresholds provides a proxy for the signal-to-noise ratio, which differs by training 309 
population--relative to the EUR training data, variants from the EAS training data with more 310 
permissive P-values improve the EAS prediction accuracy. These results indicate that larger 311 
EAS studies will be needed to explain similar case/control variance as currently explained in 312 
EUR individuals. Further, although individual loci typically have the same direction and similar 313 
magnitude across populations, aggregating variants that differentially tag causal loci across 314 
populations for genetic risk prediction results in considerable variability in prediction accuracy.  315 
 316 
DISCUSSION 317 
To date, most large-scale psychiatric genetics studies have been based on samples of primarily 318 
EUR ancestry6. To increase global coverage, we compiled the largest non-European psychiatric 319 
genetics cohort to date, and leveraged its size and diversity to provide new insights into the 320 
genetic architecture of schizophrenia. This study included all available major genotyped 321 
schizophrenia samples of East Asia ancestry, and presented analyses that had never been 322 
performed with sufficient power in psychiatric genetics.  323 
When a single population is used to identify the disease-associated loci, the discovery is 324 
skewed towards disease-associated variants that have greater allele frequency in that 325 
population (Extended Data Figure 8). When multiple populations are used, disease-associated 326 
variants are equally represented across the allele frequency spectrum in these populations 327 
(Extended Data Figure 8). This demonstrates that including global samples improves power to 328 
find disease associations for which the power varies across populations. In this study, for 329 
example, more EUR than EAS samples would be required to detect around half of the new loci, 330 
as the MAF is higher in EAS than in EUR in these loci.  331 
For traits like body mass index and autoimmune diseases, we observed heterogeneity 332 
across populations in genetic effects26,52, which may point to interactions between genetic 333 
associations and environment factors and/or other genetic loci. In contrast, for schizophrenia, 334 
we did not find significant heterogeneity across EAS and EUR ancestries. Analyses in genetic 335 
heritability, genetic correlation, gene-set enrichment and natural selection signatures all 336 
converge to the same conclusion that the schizophrenia biology is substantially shared across 337 
EAS and EUR, and likely, across other major world populations. This remarkable genetic 338 
correlation (rg=0.98) across populations suggests, for the first time, that schizophrenia genetic 339 
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factors operate in an obedient fashion between ethnic and cultural backgrounds, and 340 
schizophrenia across the world share the same genetic causes. Given that the mainstay 341 
epidemiological factors (migration, urbanity and substance misuse) differ across populations, 342 
this finding also suggests any specific genetic liability to schizophrenia acting via these routes is 343 
minimal. 344 
We note that a direct comparison of the effect sizes estimated in EAS with those 345 
estimated in EUR has reduced accuracy as we do not know the exact schizophrenia causal 346 
variants. This is further complicated by inflation in effect size estimates due to the winner’s 347 
curse, which are of different magnitudes due to the sample size. Increasing the sample size, 348 
especially in those of non-European ancestries, will reduce the bias and enable a better 349 
isolation of causal variants, leading to a more precise comparison of the genetic effect size 350 
across populations. 351 
The major histocompatibility complex (MHC) hosts the strongest schizophrenia 352 
association in EUR53. In this study, we did not find a significant schizophrenia association in 353 
MHC in EAS. An earlier EUR study54 mapped the MHC associations to a set of variants (in LD) 354 
at both distal ends of the extended MHC (lead variant: rs13194504) and the complement 355 
component 4 (C4). Consistent with several studies of the Chinese ancestries7,8,55,56, none of 356 
these associations was significant in EAS in this study. We attribute this partially to low 357 
frequencies: rs13194504 has MAF < 1% in EAS comparing with 9% in EUR, and the C4-BS 358 
allele is extremely uncommon in samples from China and Korea57,58. Another reason may be the 359 
EUR-specific LD. In EUR, multiple protective alleles that contribute to the MHC associations are 360 
all on the same haplotype across about 6 Mb, due to an extremely long and EUR-specific 361 
haplotype that generates LD patterns at 5-Mb scale. This is also the reason that that association 362 
signals span so many Mb of genome, and the aggregate association signal (at variants that are 363 
in partial LD to multiple signals) is stronger than the signals at the individual associations.  364 
Two recent studies using individuals of Chinese ancestries7,8 reported variants in MHC 365 
significantly associated with schizophrenia (rs115070292 and rs111782145 respectively, with 366 
very weak LD with each other: R2=0.07), which are different and not in LD with the EUR MHC 367 
associations. rs115070292, from Yu et al.7, is more frequent in EAS (12%) than in EUR (2%) 368 
with P = 10-9 using 4,384 cases and 5,770 controls of Chinese ancestry. This variant was not 369 
significantly associated in our study (P = 0.44) even though some samples of the Chinese 370 
studies were included in the current study (BJM-1, 1,312 cases and 1,987 controls). OR 371 
estimated from these shared samples marginally differs from that estimated using all EAS 372 
samples (P=0.018), and this association showed marginally significant heterogeneity across all 373 
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EAS samples (P=0.039). Similarly, we did not replicate the association at rs111782145 from Li 374 
et al.8 (P = 0.47) despite of the sample overlap (2,555 cases and 3,952 controls). Further 375 
investigation with more samples is needed to delineate MHC associations in EAS and Chinese. 376 
Genetic associations usually implicate a large genomic region and thus it can be 377 
challenging to map their molecular functions. We designed a novel algorithm to leverage the 378 
population diversity to fine-map schizophrenia associations to precise sets of variants. Using 379 
this algorithm we reduced the number of candidate variants associated with schizophrenia and 380 
facilitated the functional interpretation of these associations. Our algorithm assumed that there 381 
is a single causal variant in a genetic locus associated with schizophrenia. Previous fine-382 
mapping studies38,59 have confirmed that this assumption is valid for most genetic loci 383 
associated with complex disorders. 384 
Finally, this large-scale EAS sample allowed us to empirically evaluate the congruence 385 
of the genetic basis of schizophrenia between EAS and EUR. In spite of a cross-population 386 
genetic correlation indistinguishable from 1, we found that polygenic risk models trained in one 387 
population have reduced performance in the other population due to different allele frequency 388 
distributions and LD structures. This highlights the importance of including all major ancestral 389 
groups in genomic studies both as a strategy to improve power to find disease associations and 390 
to ensure the findings have maximum relevance for all populations. 391 
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 602 
Figure 1 | Genetic associations in East Asian populations. Horizontal line indicates the 603 
genome-wide significance threshold. a, Manhattan plot for schizophrenia genetic associations 604 
using East Asian samples (Stages 1 and 2). b, Regional association plot for a locus associated 605 
with schizophrenia using EAS Stage 1 samples.   606 
18 
 607 
Figure 2 | Schizophrenia associations in EUR and EAS samples. a, Log odds ratio of top 608 
schizophrenia associations estimated in EUR and EAS samples. Error bars indicate 95% 609 
confidence interval. Dashed line indicates the diagonal line, and the solid line indicates the 610 
regression line with intercept at 0. b, Manhattan plot for the schizophrenia genetic associations 611 
from the EAS (Stages 1 and 2) + EUR meta-analysis. 612 
 613 
  614 
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 615 
Figure 3 | Trans-ethnicity fine-mapping maps improves resolution. a, an association was 616 
mapped to a single variant (rs11587347) after adding EAS samples and using the trans-617 
ancestry fine-mapping approach. Regional association plots were generated using 618 
http://locuszoom.org/ and LD from 1000 Genomes Project Phase 3 EUR subjects. b, LD with 619 
the lead variant (rs11587347). Red: perfect LD (R2=1); white: no LD (R2=0). c, The lead variant 620 
(rs11587347) has strong association significance in both populations and low heterogeneity 621 
across populations. d, Number of variants in the 95% credible set using the trans-ancestry 622 
(EAS+EUR) and publish fine-mapping approaches (EUR only).   623 
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 624 
Figure 4 | Genetic risk prediction accuracy in EAS from EAS or EUR training data. 625 
Polygenic risk scores were computed with GWAS summary statistics from EAS and EUR 626 
populations as training sets. EAS risk alleles and weights were computed with a leave-one-out 627 
meta-analysis approach across the 13 Stage 1 samples. Error bars indicate the 95% confidence 628 
interval. LD panel for clumping is from EUR and EAS 1000 Genomes Phase 3 samples. a, 629 
Case/control variance explained in EAS samples by variants from EAS and EUR training data 630 
with a P-value more significant than the threshold. b, Case/control variance explained by the n 631 
most significant independent variants.  632 
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        Stage 1 Stage 2 Combined 
SNP Chr BP AL P OR P OR P OR 
rs4660761 1 44440146 A/G 3.6E-06 0.91 3.53E-04 0.92 5.08E-09 0.91 
rs848293 2 58382490 A/G 3.7E-10 0.90 3.10E-09 0.87 9.87E-18 0.89 
rs17592552 2 201176071 T/C 8.4E-10 0.86 2.68E-05 0.89 1.50E-13 0.88 
rs2073499 3 50374293 A/G 1.1E-09 0.89 2.14E-05 0.91 1.33E-13 0.90 
rs76442143 3 51043599 T/C 6.9E-09 1.14 1.03E-02 1.08 6.40E-10 1.12 
rs10935182 3 136137422 A/G 1.3E-06 0.90 1.33E-04 0.90 7.08E-10 0.90 
rs4856763 3 161831675 A/G 3.9E-06 0.92 8.54E-06 0.91 1.73E-10 0.92 
rs13096176 3 180752138 T/C 3.1E-07 0.88 2.21E-03 0.90 3.35E-09 0.89 
rs6832165 4 24270210 C/G 3.7E-08 1.12 3.70E-01 1.08 2.79E-08 1.12 
rs13142920 4 176728614 A/C 9.5E-05 0.93 5.85E-06 0.89 4.85E-09 0.92 
rs4479913 6 165075210 A/G 3.6E-07 1.13 9.98E-05 1.12 1.53E-10 1.12 
rs320696 7 137047137 A/C 5.5E-08 0.90 1.07E-02 0.93 2.81E-09 0.91 
rs11986274 8 38259481 T/C 5.1E-04 1.07 2.73E-06 1.11 1.44E-08 1.08 
rs2612614 8 65310836 A/G 2.2E-08 1.14 4.51E-02 1.06 1.62E-08 1.11 
rs4147157 10 104536360 A/G 6.6E-10 0.90 3.87E-07 0.89 1.32E-15 0.89 
rs10861879 12 108609634 A/G 4.8E-07 1.09 5.00E-03 1.07 1.18E-08 1.08 
rs1984658 12 123483426 A/G 5.1E-11 0.89 2.14E-04 0.92 8.62E-14 0.90 
rs9567393 13 32763757 A/G 3.5E-08 1.11 4.37E-03 1.07 1.13E-09 1.09 
rs9890128 17 1273646 T/C 3.5E-08 0.90 2.44E-02 0.91 2.61E-09 0.90 
rs11665111 18 77622996 T/C 5.2E-06 1.08 6.89E-04 1.09 1.46E-08 1.09 
rs55642704 18 77688124 T/C 1.1E-06 1.09 7.11E-06 1.10 3.76E-11 1.09 
 634 
Table 1. Genome-wide significant loci in the East Asian populations. BP: genomic position in 635 
HG19. AL: Reference and non-reference alleles, OR: Odds-ratio, P: P-value.  636 
  637 
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METHODS 638 
Overview of samples 639 
The following samples were used in this study: 640 
EAS samples, full-genome: genome-wide genotype data was obtained from 16 EAS 641 
samples from Singapore, Japan, Indonesia, Korea, Hong Kong, Taiwan, and mainland China 642 
(Extended Data Table 1). Two of these samples (TAI-1 and TAI-2) had parents off-spring trios, 643 
and were processed as case/pseudo-controls. DSM-IV was used for diagnosing all 644 
schizophrenia cases in these samples except for the tros (TAI-1 and TAI-2), for which DIGS was 645 
used. All samples were processed according to quality control (QC) procedures reported in ref 646 
2, with details reported in following sections. After QC, genotypes were phased and imputed 647 
against the 1000 Genomes Project Phase 3 reference panel6. Principal component analysis 648 
(PCA) was conducted across samples via imputed best guess genotypes to identify and remove 649 
overlapping samples across datasets, cryptic related samples and population outliers. Eight 650 
principal components (PCs) that are associated to the case-control status were included in 651 
univariate logistic regression to control for the population stratification in each sample.  652 
EAS samples, selected variants: summary statistics was obtained for a set of variants 653 
from four EAS samples (BJM-2, BJM-3, BJM-4, BIX-5) which had been analyzed in published 654 
studies7,8. The summary statistics included odds ratio, standard error, reference and tested 655 
alleles for variants that have P<10-5 in either Stage 1 or the meta-analysis combining Stage 1 656 
and EUR samples. Between 22,156 and 31,626 variants were available after the exclusion of 657 
strand ambiguous60 variants (Supplementary Table 1). 658 
EUR samples: Genotypes for EUR schizophrenia patients and controls were obtained 659 
from the Psychiatric Genomics Consortium as reported in ref 2. All samples of EUR ancestry 660 
were included in this study except for the deCODE samples (1,513 cases and 66,236 controls). 661 
We also like to note that three samples of EAS ancestry reported in this publication were not 662 
included in the EUR samples in our analysis but were included in the EAS samples (IMH-1, 663 
HNK-1 and JPN-1). The same procedures used in processing EAS samples were applied to the 664 
EUR samples. 665 
 666 
Quality control  667 
Quality control procedures were carried out as part of the RICOPILI pipeline 668 
(https://sites.google.com/a/broadinstitute.org/ricopili/home) with the following steps and 669 
parameters: 1) Excluding variants with call rate below 95%; 2) Excluding subjects with call rate 670 
below 98%; 3) Excluding monomorphic variants; 4) Excluding subjects with inbred coefficient 671 
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above 0.2 and below -0.2; 5) Excluding subjects with mismatch in reported gender and 672 
chromosome X computed gender; 6) Excluding variants with missing rate differences greater 673 
than 2% between cases and controls; 7) Subsequent to step 6, exclude variants with call rate 674 
below 98%; and 8) Exclude variants in violation of Hardy-Weinberg equilibrium (P < 10-6 for 675 
controls or P < 10-10 for cases). Numbers of variants or subjects removed in each step were 676 
reported in Supplementary Table 1.  677 
 678 
Phasing and imputation 679 
All datasets were phased using SHAPEIT61 and IMPUTE262 using regular steps and 680 
parameters. Additional processing for trios (TAI-1 and TAI-2) was carried out such that 681 
case/pseudo-controls were identified and imputed. All samples were imputed to the 1000 682 
Genomes Project Phase 3 reference panel63 (2504 subjects, including 504 EAS subjects). 683 
Imputation procedures resulted in dosage files and best guess genotypes in PLINK64 binary 684 
format. The former was used for subsequent association analysis and the latter was used in the 685 
PCA and PRS analyses. 686 
 687 
Sample overlaps, population outliers and population stratification 688 
We used Eigenstrat65 to calculate the principal components for all the samples using the best 689 
guess genotypes from imputation (Extended Data Figure 9b). We computed the identity-by-690 
descent matrix to identify intra- and inter- dataset sample overlaps. Samples with pi-hat > 0.2 691 
were extracted, followed by Fisher-Yates shuffle on all samples. The number of times with 692 
which each sample was related to another sample was tracked and samples that were related 693 
to more than 25 samples were removed. When deciding which samples to retain, trio were 694 
preferred, followed by cases, and thereafter a random sample for each related pair was 695 
removed, 704 individuals were removed.  696 
To identify population outliers, k-means clustering was conducted using the first 20 PCs 697 
from PCA and covariates representing each of the 13 Stage 1 samples. Guided by results of k-698 
means clustering and visual inspection of PCA plots, 46 individuals were identified as outliers 699 
and were excluded. Further population-level inspection was carried out by merging the 1000 700 
Genomes Project Phase 1 reference samples with Stage 1 samples and conducting PCA 701 
(Extended Data Figure 9a). Using similar approaches reported above, no further samples were 702 
excluded as population outliers.  703 
24 
Eight PCs that are associated with case/control status with P < 0.2 were used as 704 
covariates for association analysis in each sample (PCs 1, 4, 5, 6, 8, 9, 15, and 19). QQ plots 705 
(Extended Data Figure 1) showed that the population structure has been well controlled.  706 
 707 
Association analysis and meta-analysis 708 
Association analysis was carried out for each sample using PLINK64 and genotype dosage from 709 
imputation. Only variants having imputation INFO ≥ 0.6 and MAF ≥ 1% were included in the 710 
analysis. We performed logistic regression with PCs identified in the prior subsection as 711 
covariates to control for population stratification within each study. Fixed-effect meta-analysis66, 712 
weighted by inverse-variance, was then used to combine the association results across 713 
samples. Meta-analysis for European samples were conducted in the same matter. In order to 714 
find independent schizophrenia associations in both EUR and EAS populations (Supplementary 715 
Table 4), we performed LD clumping twice using the 1000 Genomes Project Phase 3 EUR and 716 
EAS reference panels respectively (with default parameters in RICOPILI). 717 
 718 
Chromosome X analysis  719 
Chromosome X genotypes were processed separately from autosomal variants. Quality control 720 
was conducted separately for males and females, using similar quality control parameters as 721 
above. Cases and pseudo-controls were built out of the trios. Phasing and imputation were then 722 
performed on males and females separately for each sample, followed by logistic regression 723 
with the same PCs, and meta-analysis combining samples (same parameters as the autosomal 724 
analyses). Results were generated for EAS Stage 1 samples and EUR-EAS combined samples 725 
(excluding BIX1, BIX2 and BIX3). EAS Stage 2, BIX1, BIX2 and BIX3 samples do not have 726 
chromosome X data and were therefore not analyzed.   727 
  728 
Genetic correlation and heritability 729 
Schizophrenia heritabilities in the observed scale for samples of EUR and EAS ancestry were 730 
estimated from their summary statistics using the LDSC21. We converted the heritabilities in the 731 
observed scale to liability scale assuming the schizophrenia population prevalence at 1%. The 732 
LD scores were pre-computed from the 1000 Genomes Project Phase 3 reference panel in EUR 733 
and EAS respectively (https://github.com/bulik/ldsc). Only autosomal variants having MAF 734 
greater than 5% in their respective population were included in the analysis, and variants in the 735 
MHC region were not included due to the long range LD.  736 
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We computed the genetic correlations between schizophrenia and other traits within 737 
EUR and across EUR and EAS. EUR and EAS (Stage 1 only) summary statistics for autosomal 738 
variants from this study were used as schizophrenia genetic association inputs for their 739 
respective populations. Traits tested included schizophrenia2, bipolar67, major depression68, 740 
anorexia nervosa69, neuroticism70, autism spectrum disorder (PGC 2015 release), attention 741 
deficit hyperactivity disorder (with samples of non-European ancestry removed, available at 742 
http://www.med.unc.edu/pgc)71, education attainment72, general intelligence73, fluid intelligence 743 
score and prospective memory result (using individuals from UK Biobank), and subjective well 744 
being (SWB)70. Only variants having MAF greater than 5% were available and included. 745 
Variants in the MHC region were excluded from the analysis. Genetic correlations within EUR 746 
were computed using LDSC with LD scores pre-computed on the 1000 Genomes Project Phase 747 
3 reference panel (503 EUR subjects). Genetic correlations across EUR and EAS were 748 
computed using POPCORN27. POPCORN uses a Bayesian approach which assumes that 749 
genotypes are drawn separately from each population and effect sizes follow the infinitesimal 750 
model. The inflation of z scores could then be modelled and a weighted likelihood function 751 
which was maximized to find heritability and genetic correlation. Genetic correlations in 752 
POPCORN were computed in the “genetic effect” mode, which estimates the correlation based 753 
on the LD covariance scores and effect sizes from summary statistics.  754 
  755 
Partitioned heritability 756 
Partitioned LDSC32 was conducted to look for heritability enrichment in diverse annotations 757 
using EAS (Stage 1) and EUR autosomal variants (summary statistics) respectively. LD scores 758 
for each annotation were computed using a combination of PLINK64 and LDSC21 using the 1000 759 
Genomes Project EAS and EUR subjects respectively. We used baseline annotations32 and 760 
additional annotations including chromatin accessibility in brain dorso-lateral prefrontal cortex 761 
through the Assay for Transposase-Accessible Chromatin using sequencing peaks (ATAC 762 
Bryois)33, conserved regions located in “ATAC Bryois” (ATAC Bryois & Conserved 763 
LindbladToh)33, and introgressed regions from Neanderthal (Neanderthal Vernot)74. Variants 764 
can be included in multiple annotations. Multi-allelic variants were removed.  765 
 766 
Gene-set analysis 767 
We performed gene and gene-set based tests using MAGMA35. Genome-wide summary 768 
statistics for autosomal variants from EAS, EUR and EAS+EUR meta-analyses were used in 769 
this analysis. Variant-to-gene annotation was performed using RefSeq NCBI37.3 with a window 770 
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of 5 Kb upstream and 1.5 Kb downstream. LD was taken from 1000 Genomes Project EAS, 771 
EUR and EUR-EAS panels respectively. The gene-based P-values were computed using F-test 772 
and multivariate linear model, and competitive tests were used for gene-set analysis. Seventy 773 
gene-sets were selected and tested in this study (Supplementary Table 7) including those from 774 
the Molecular Signatures Database databases75, related to psychiatric diseases36,76,77 and from 775 
‘gwaspipeline’ (https://github.com/freeseek/gwaspipeline/blob/master/makegenes.sh). Gene-776 
sets were ranked for EUR, EAS and EAS+EUR analyses respectively. The top ranking gene-777 
sets were compared across analyses to identify common schizophrenia pathways. Additionally, 778 
Wilcoxon sign rank tests was conducted to compare the ranking of gene-sets between the EUR 779 
and EAS datasets.  780 
 781 
Natural selection analysis 782 
We used the CHB and CEU panels from the 1000 Genomes Project Phase 3 to investigate the 783 
natural selection signatures in schizophrenia-associated loci for EAS and EUR populations 784 
respectively. We used the following selection signatures, with their sensitivity to timeframes 785 
discussed in ref 3. integrated Haplotype Score (iHS): iHS captures the haplotype homozygosity 786 
at a given variant. We calculated iHS using the R rehh package78. Genetic distance between 787 
variants was determined using HapMap phase II genetic map. Ancestral and derived alleles 788 
were obtained from the 1000 Genome project, which inferred the ancestral state using six 789 
primates on the EPO (Enredo-Pecan-Ortheus) pipeline. Only bi-allelic variants that have MAF ≥ 790 
5% were included in the analysis. Cross Population Extended Haplotype Homozygosity 791 
(XPEHH)79: XPEHH detects variants under selection in one population but not the other. We 792 
used CEU as the reference panel when calculating XPEHH for CHB and vice versa. Fixation 793 
index (Fst): Fst measures the population differentiation due to genetic structure. We estimated 794 
Fst using the Weir and Cockerham approach80, which is robust to sample size effects. Absolute 795 
derived allele frequency difference (|∆DAF|): |∆DAF| measures population differentiation 796 
between CHB and CEU populations. Composite of Multiple signals (CMS)81–83: CMS combines 797 
iHS, XPEHH, Fst and |∆DAF|. As a result, CMS potentially has better power to detect the 798 
selection signature. For each variant, , in which  is the rank of the variant using 799 
method , sorted by increasing P-values, divided by the total number of variants. B statistic: B 800 
statistic measures the background selection. We calculated the B statistic as in ref 84. 801 
 802 
Trans-ethnicity fine-mapping 803 
27 
For a disease-associated genetic locus, fine-mapping defines a “credible set” of variants that 804 
contains the causal variant with certain probability (e.g., 99% or 95%). The Bayesian fine-805 
mapping approaches2,38,85,86 have been widely used for studies of a single ancestry. Here, we 806 
extended a Bayesian fine-mapping approach85 (Defining credible sets, Methods) to studies of 807 
more than one ancestry.  808 
Assume  represents the data including the genotype matrix  for all the  variants 809 
and disease status  for  individuals, and  represents a collection of model parameters. We 810 
define the model, denoted by , as the causal status for the  variants in locus: , in 811 
which  is the causal status for variant .  if the variant  is causal, and   if it is not. 812 
We assume that there is one and only one genuine signal for each locus, and the causal variant 813 
is the same across all ancestries; therefore, one and only one of the  variants is causal: 814 
. For convenience, we define  as the model in which only variant  is causal, and 815 
 as the model in which no variant is causal (null model). The probability of model  (where 816 
variant  is the only causal variant in the locus) given the data ( ) can be calculated using 817 
Bayes’s rule: 818 
. 819 
With the steepest descent approximation, the assumption of a flat prior on the model 820 
parameters ( ), and the assumption of one causal variant per locus (equation 2 in ref 85), 821 
 can be approximated as: 822 
, (1) 823 
 in which  is the sample size. We denote  as the  test statistic for variant , which 824 
can be calculated from the P-value from the meta-analysis combining EAS and EUR samples. 825 
Using equation 3 in ref 85, we have  826 
 .    (2) 827 
 is the prior probability that variant  is causal. We have shown that schizophrenia 828 
causal variants have consistent genetic effect across populations. Therefore we model the prior 829 
probability as a function of the heterogeneity measured in :  830 
.     (3) 831 
 Using equations 2 and 3,  in equation 1 can be calculated as 832 
28 
. 833 
We only use Stage 1 samples in fine-mapping so the variants have the same sample 834 
size (assuming all variants have good imputation quality). Therefore, ,  and  835 
 can be regarded as constants,   836 
. 837 
 The normalized causal probability for variant  is then 838 
, 839 
and the 95% credit set of variants is defined as the smallest set of variants, , such that  840 
.  841 
 842 
Polygenic risk score analysis  843 
We constructed PRS using a pruning and thresholding approach in a study set of EAS 844 
individuals with training summary statistics from either EUR or EAS individuals. In the former 845 
case, we used summary statistics from all EUR individuals in this study; in the latter case, we 846 
used a leave-one-out meta-analysis approach across the 13 Stage 1 samples to build PRS.  847 
For the EUR training data, we extracted EUR individuals (FIN, GBR, CEU, IBS, TSI) 848 
from 1000 Genomes Project63 Phase 3 as an LD reference panel to greedily clump variants. For 849 
the EAS LD reference panel, we created two panels: 1) an analogous EAS panel (CDX, CHB, 850 
CHS, JPT, KHV) from 1000 Genome Project63 Phase 3 (Fig. 4 and Extended Data Fig. c and d), 851 
and 2) an LD panel from best guess genotypes from each cohort in the study (Extended Data 852 
Fig. a,b,e,f). For both EAS and EUR prediction sets, we filtered to variants with a MAF greater 853 
than 1% in each respective populations, and removed indels and strand ambiguous variants. 854 
We subset each list of variants to those in the summary statistics with an imputation INFO > 0.9. 855 
We then selected approximately independent loci at varying P-value thresholds or top-ranking n 856 
variants using an LD threshold of R2 ≤ 0.1 in a window of 500 kilobase pairs in PLINK64 with the 857 
--clump flag. We treated the MHC with additional caution to minimize overfitting in this region, 858 
selecting only the most significant variant from the HLA region. To profile variants, we multiplied 859 
the log odds ratio for selected variants by genotypes and summed these values across the 860 
genome in PLINK64 using the --score flag for each of the 13 EAS Stage 1 samples. We 861 
assessed case/control variance explained by computing Nagelkerke’s and a liability-scale 862 
29 
pseudo-R2 as in Lee et al.87 by comparing a full model with the PRS and 10 principal 863 
components with a model excluding the PRS.  864 
 865 
Data availability     866 
Summary statistics from this study can be downloaded from 867 
https://personal.broadinstitute.org/hhuang/PGC_SCZ_EAS/. Raw genotype data that support 868 
the findings of this study are available from the Psychiatric Genomics Consortium but 869 
restrictions apply to the availability of these data, which were used under licence for the current 870 
study, and so are not publicly available. Data are, however, available from the corresponding 871 
authors upon reasonable request and with the permission of the Psychiatric Genomics 872 
Consortium.  873 
 874 
Code availability  875 
Computer code used to perform QC, PCA, imputation, association test and meta-analysis can 876 
be downloaded from https://github.com/Nealelab/ricopili/wiki. Code for other analyses is 877 
available upon request.  878 
 879 
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Extended Data Figure 1. Quantile-quantile (QQ) plots. QQ plots for each EAS stage-1 samples (a-m) 2 
and meta-analyses including all EAS Stage 1 samples (n), Stages 1 and 2 samples (o) and all EUR and 3 
EAS (Stages 1 and 2) samples (p).Blue line indicates the expected null distribution, and the shaded area 4 
indicates the 95% confidence interval of the null distribution. Legend: “lambda”=genomic inflation factor; 5 
“lamda1000”=genomic inflation factor for an equivalent study of 1000 cases and 1000 controls; and 6 
“N(pvals)”=number of variants used in the plot. Autosomal variants that have minor allele frequency ≥ 1% 7 
and INFO ≥ 0.6 from imputation were included. Observed P-values were capped at 10-12 for visualization 8 
purpose.  9 
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 10 
Extended Data Figure 2 | Heritability and genetic correlation. a, Heritability (h2) for the EAS and EUR 11 
samples. b, Genetic correlation between schizophrenia and other traits within EUR (blue) and across 12 
EAS and EUR (red). Error bars indicate the 95% confidence interval. c, Enrichment and its corresponding 13 
significance for heritability partitioned based on various annotations. d, Scatterplot showing the 14 
enrichment versus the significance for heritability partitioned based on various annotations. More details 15 
are available in Methods.  16 
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 17 
Extended Data Figure 3 | Gene-sets implicated by schizophrenia genetic associations. a, Overlap 18 
of implicated gene-sets across EUR and EAS samples. b, List of the top 10 gene-sets implicated in the 19 
EAS and EUR samples and their P-values in -log10 scale. Descriptions of the gene-sets are available in 20 
Supplementary Table 8.  21 
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 22 
Extended Data Figure 4 | Natural selection signals in EAS and EUR. a, Distributions of natural 23 
selection signals in the top 100 schizophrenia associations in EAS (red) and EUR (blue). b, Scatterplot of 24 
Fst versus the heterogeneity of effect size for schizophrenia associations. More details are available in 25 
Methods.   26 
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 27 
Extended Data Figure 5 | Trans-ethnicity fine-mapping. Illustration of the fine-mapping method.   28 
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 29 
Extended Data Figure 6 | Variance explained for schizophrenia associations across EUR and EAS 30 
samples. Genome-wide significant associations that have variance explained greater than 0.05% in 31 
either EAS or EUR samples were plotted. One locus can host multiple independent associations. 32 
Different MAF is defined as Fst>0.01, and different OR is defined as heterogeneity test P-value < 0.05 33 
after bonferroni correction. Nearest genes to the associations were used as labels for associations when 34 
the text space is available, with the exception that the MHC locus was labeled as “MHC”.  35 
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 36 
Extended Data Figure 7 | Genetic risk prediction accuracy in EAS from EAS or EUR training data. 37 
As in Fig. 4, PRS shows case/control variance explained with EUR and EAS samples using a leave-one-38 
out meta-analysis approach for the EAS samples. Error bars indicate the 95% confidence intervals. a,b) 39 
Liability-scale variance explained when LD panel for clumping is from EUR 1000 Genomes Phase 3 40 
samples and best-guess genotypes are from each EAS cohort. c,d) Nagelkerke’s R2 for EAS prediction 41 
accuracy when LD panel for clumping is from EUR and EAS 1000 Genomes Phase 3 samples. E-F) 42 
Nagelkerke’s R2 for EAS prediction accuracy when LD panel for clumping is from EUR 1000 Genomes 43 
Phase 3 samples and best-guess genotypes are from each EAS cohort.  44 
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 45 
Extended Data Figure 8 | Ratio of the heterozygote rate in EAS to that in EUR for existing and new 46 
loci. Het(EAS) and Het(EUR), calculated as , are the heterozygote rates for a variant in EAS 47 
and EUR respectively, in which  is the variant allele frequency in EAS or EUR. Power to identify genetic 48 
associations increases with the expected non-centrality parameter for the association, which is 49 
proportional to the heterozygote rate. Therefore we use the ratio of the heterozygote rate in EAS to that in 50 
EUR as a measure of the relative power to identify genetic association of the same effect size in the two 51 
populations. A ratio greater than 1 means EAS samples have more power to identify the association and 52 
vice versa. Existing loci are those that are genome-wide significant in the previous study of European 53 
ancestry2, and new loci are those that are genome-wide significant just in this study combining EAS and 54 
EUR samples.   55 
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 56 
Extended Data Figure 9 | Principal component analysis of EAS samples. a, EAS samples mapped to 57 
the global principal components created using 1000 Genomes Project Phase 1 samples. b, EAS cases 58 
and controls mapped respectively to principal components created using all EAS samples in this study.  59 
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Extended Data Table 1 | Overview of samples and variants  60 
a) Sample characteristics 61 
Study  Case Control Chip Design Region Raw data Stage X chr. 
IMH-1 856 946 I_1M CC Singapore Y 1 Y 
IMH-2 766 913 I_OZH CC Singapore Y 1 Y 
HNK-1 476 2018 I_610 CC Hong Kong Y 1 Y 
JPN-1 547 540 A_SNP5.0 CC Japan Y 1 Y 
BIX-1 1045 2272 A_SNP6.0 CC Mainland China Y 1 N 
BIX-2 1021 1001 A_SNP6.0 CC Mainland China Y 1 N 
BIX-3 489 679 A_SNP6.0 CC Mainland China Y 1 N 
XJU-1 1846 947 I_OZH CC Mainland China Y 1 Y 
UMC-1 2260 2241 I_Psyc CC Mainland China Y 1 Y 
UWA-1 988 1001 I_Psyc CC Indonesia Y 1 Y 
BJM-1 1312 1987 I_OZH CC Mainland China Y 1 Y 
TAI-1 1109 1109 I_Psyc TRIO Taiwan Y 1 Y 
TAI-2 590 590 I_Psyc TRIO Taiwan Y 1 Y 
KOR-1 687 492 A_KB CC Korea Y 2 N 
SIX-1 192 47 I_Psyc CC Mainland China Y 2 N 
BIX-4 399 478 I_GSA CC Mainland China Y 2 N 
BJM-2 746 1599 I_610 CC Mainland China N 2 N 
BJM-3 1595 1447 I_660W CC Mainland China N 2 N 
BJM-4 710 680 I_OZH CC Mainland China N 2 N 
BIX-5 5144 14375 A_SNP6.0, A_CHB1, I_1M CC Mainland China N 2 N 
Total 22,778 35,362          
b) Meta-analysis summary 62 
  EAS Stage 1  EAS Stages 1&2 EUR EAS Stages 1&2 + EUR 
N cases 13,305 22,778 33,640 56,418 
N controls 16,244 35,362 43,456 78,818 
N cases + controls 29,549 58,140 77,096 135,236 
N variants (autosomes) 9,657,549 9,607,215 9,699,101  12,064,345 
N variants (x chr.) 331,372 331,372 331,138 383,603 
λ 1.145 1.133 1.471 1.350 
λ_1000 1.010 1.005 1.012 1.005 
N associations 8 21 116 208 
N associated loci 7 19 102 176 
a, EAS samples used in this study. Details can be found in Supplementary Information. Sample numbers are post-63 
QC. Chip: I_1M: Human1M-Duo v3.0 DNA Analysis BeadChip; I_OZH: Illumina Infinium OmniZhongHua-8; I_610: 64 
Human610-Quad BeadChip; I_Psyc: Illumina Infinium PsychArray-24; A_SNP6.0: Genome-Wide Human SNP Array 65 
6.0; A_SNP5.0: Genome-Wide Human SNP Array 5.0; A_KB: Affy Korean Biobank chip; A_CHB1: Affy Axiom CHB1 66 
chip; I_GSA: Illumina Infinium Global Screening Array. All chips have genome-wide coverage. Design: study design, 67 
either case-control (CC) or trio (TRIO). Raw data: whether individual-level genotypes were available and used in this 68 
study. X chr.: whether the X chromosome genotypes were available and used. b, Summary of samples and variants 69 
in this study. λ is the genomic inflation factor using postQC and imputation autosomal variants with MAF cut-off of 1% 70 
and imputation INFO cut-off of 0.6. λ_1000 is the genomic inflation factor for an equivalent study of 1000 cases and 71 
1000 controls. N variants report the number of variants after the meta-analysis that have imputation INFO≥0.6 and 72 
MAF≥1%, broken down to autosomes and X chromosomes respectively.  73 
